{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:46:56Z","timestamp":1790790416342,"version":"4.1.0"},"reference-count":100,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Numerous vaccines have now been developed using the mRNA platform. In this approach, mRNA coding for a viral antigen is in vitro synthesized and injected into the host leading to exogenous protein expression and robust immune responses. Vaccines can be rapidly developed utilizing the mRNA platform in the face of emerging pandemics. Additionally, the mRNA coding region can be easily manipulated to test novel hypotheses in order to combat viral infections which have remained refractory to traditional vaccine approaches. Flaviviruses are a diverse family of viruses that cause widespread disease and have pandemic potential. In this review, we discuss the mRNA vaccines which have been developed against diverse flaviviruses.<\/jats:p>","DOI":"10.3390\/vaccines9020148","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T18:46:31Z","timestamp":1613155591000},"page":"148","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["mRNA Vaccines against Flaviviruses"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5692-6249","authenticated-orcid":false,"given":"Clayton J.","family":"Wollner","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, University of Illinois College of Medicine, Chicago, IL 60612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5344-118X","authenticated-orcid":false,"given":"Justin M.","family":"Richner","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Illinois College of Medicine, Chicago, IL 60612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"key":"ref_1","first-page":"712","article-title":"Flaviviridae","volume":"Volume One","author":"Knipe","year":"2013","journal-title":"Fields Virology"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Holbrook, M.R. (2017). Historical Perspectives on Flavivirus Research. Viruses, 9.","DOI":"10.3390\/v9050097"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1126\/science.aaf5036","article-title":"Zika virus in the Americas: Early epidemiological and genetic findings","volume":"352","author":"Faria","year":"2016","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1016\/j.vaccine.2017.03.032","article-title":"Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease","volume":"35","author":"Barrett","year":"2017","journal-title":"Vaccine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.clinthera.2017.07.001","article-title":"Progress and Works in Progress: Update on Flavivirus Vaccine Development","volume":"39","author":"Collins","year":"2017","journal-title":"Clin. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1084\/jem.65.6.787","article-title":"The Use of Yellow Fever Virus Modified by in Vitro Cultivation for Human Immunization","volume":"65","author":"Theiler","year":"1937","journal-title":"J. Exp. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1056\/NEJM198809083191004","article-title":"Protection against Japanese encephalitis by inactivated vaccines","volume":"319","author":"Hoke","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01240711","article-title":"Experimenteller und epidemiologischer Beitrag zur aktiven Immunisierung gegen die Fr\u00fchling-Sommer-Zeckenencephalitis","volume":"2","author":"Smorodintseff","year":"1941","journal-title":"Arch. F\u00fcr die Gesamte Virusforsch."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4161\/hv.26902","article-title":"Japanese encephalitis: The virus and vaccines","volume":"10","author":"Yun","year":"2014","journal-title":"Hum. Vaccin Immunother"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(08)60800-4","article-title":"Tick-borne encephalitis","volume":"371","author":"Lindquist","year":"2008","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kaiser, J.A., and Barrett, A.D.T. (2019). Twenty Years of Progress Toward West Nile Virus Vaccine Development. Viruses, 11.","DOI":"10.3390\/v11090823"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"a029371","DOI":"10.1101\/cshperspect.a029371","article-title":"Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials","volume":"10","author":"Harris","year":"2018","journal-title":"Cold Spring Harb. Perspect Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S334","DOI":"10.1016\/j.amepre.2015.09.006","article-title":"Trials and Tribulations on the Path to Developing a Dengue Vaccine","volume":"49","author":"Thomas","year":"2015","journal-title":"Am. J. Prev. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.chom.2018.05.021","article-title":"Zika Virus Vaccine: Progress and Challenges","volume":"24","author":"Shan","year":"2018","journal-title":"Cell Host Microbe"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-020-0159-8","article-title":"The promise of mRNA vaccines: A biotech and industrial perspective","volume":"5","author":"Jackson","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Kis, Z., Kontoravdi, C., Shattock, R., and Shah, N. (2020). Resources, Production Scales and Time Required for Producing RNA Vaccines for the Global Pandemic Demand. Vaccines, 9.","DOI":"10.3390\/vaccines9010003"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1038\/s41467-018-05482-0","article-title":"Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies","volume":"9","author":"Pardi","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1128\/JVI.01786-15","article-title":"Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin","volume":"90","author":"Brazzoli","year":"2016","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.omtn.2019.03.003","article-title":"Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques","volume":"15","author":"Pardi","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Schnee, M., Vogel, A.B., Voss, D., Petsch, B., Baumhof, P., Kramps, T., and Stitz, L. (2016). An mRNA Vaccine Encoding Rabies Virus Glycoprotein Induces Protection against Lethal Infection in Mice and Correlates of Protection in Adult and Newborn Pigs. PLoS Negl. Trop Dis., 10.","DOI":"10.1371\/journal.pntd.0004746"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: An open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kose, N., Fox, J.M., Sapparapu, G., Bombardi, R., Tennekoon, R.N., de Silva, A.D., Elbashir, S.M., Theisen, M.A., Humphris-Narayanan, E., and Ciaramella, G. (2019). A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection. Sci. Immunol., 4.","DOI":"10.1126\/sciimmunol.aaw6647"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Nelson, C.S., Jenks, J.A., Pardi, N., Goodwin, M., Roark, H., Edwards, W., McLellan, J.S., Pollara, J., Weissman, D., and Permar, S.R. (2020). Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization. J. Virol., 94.","DOI":"10.1128\/JVI.00186-20"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Anderson, E.J., Rouphael, N.G., Widge, A.T., Jackson, L.A., Roberts, P.C., Makhene, M., Chappell, J.D., Denison, M.R., Stevens, L.J., and Pruijssers, A.J. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N. Engl. J. Med., 2020.","DOI":"10.1056\/NEJMoa2028436"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2\u2014Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1182\/blood.V66.5.1149.1149","article-title":"Half-lives of beta and gamma globin messenger RNAs and of protein synthetic capacity in cultured human reticulocytes","volume":"66","author":"Ross","year":"1985","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","article-title":"Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1101\/gad.5.11.2108","article-title":"The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency","volume":"5","author":"Gallie","year":"1991","journal-title":"Genes Dev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/clinchem\/48.10.1647","article-title":"Stability of endogenous and added RNA in blood specimens, serum, and plasma","volume":"48","author":"Tsui","year":"2002","journal-title":"Clin. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Kariko","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-62703-260-5_3","article-title":"HPLC purification of in vitro transcribed long RNA","volume":"969","author":"Weissman","year":"2013","journal-title":"Methods Mol. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Kariko","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA","volume":"15","author":"Baiersdorfer","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Kariko","year":"2005","journal-title":"Immunity"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0140-6736(63)92585-6","article-title":"Foreign nucleic acids as the stimulus to make interferon","volume":"2","author":"Isaacs","year":"1963","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"9329","DOI":"10.1093\/nar\/gkr586","article-title":"Nucleoside modifications in RNA limit activation of 2\u2019-5\u2019-oligoadenylate synthetase and increase resistance to cleavage by RNase L.","volume":"39","author":"Anderson","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jconrel.2015.08.007","article-title":"Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes","volume":"217","author":"Pardi","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Shirai, S., Kawai, A., Shibuya, M., Munakata, L., Omata, D., Suzuki, R., and Yoshioka, Y. (2020). Lipid Nanoparticle Acts as a Potential Adjuvant for Influenza Split Vaccine without Inducing Inflammatory Responses. Vaccines, 8.","DOI":"10.3390\/vaccines8030433"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.vaccine.2015.10.132","article-title":"A novel lipid nanoparticle adjuvant significantly enhances B cell and T cell responses to sub-unit vaccine antigens","volume":"34","author":"Swaminathan","year":"2016","journal-title":"Vaccine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.omtn.2019.08.001","article-title":"Expression Kinetics and Innate Immune Response after Electroporation and LNP-Mediated Delivery of a Self-Amplifying mRNA in the Skin","volume":"17","author":"Huysmans","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Nikonov, A., Molder, T., Sikut, R., Kiiver, K., Mannik, A., Toots, U., Lulla, A., Lulla, V., Utt, A., and Merits, A. (2013). RIG-I and MDA-5 detection of viral RNA-dependent RNA polymerase activity restricts positive-strand RNA virus replication. PLoS Pathogens, 9.","DOI":"10.1371\/journal.ppat.1003610"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Zhong, Z., Portela Catani, J.P., Mc Cafferty, S., Couck, L., Van Den Broeck, W., Gorle, N., Vandenbroucke, R.E., Devriendt, B., Ulbert, S., and Cnops, L. (2019). Immunogenicity and Protection Efficacy of a Naked Self-Replicating mRNA-Based Zika Virus Vaccine. Vaccines, 7.","DOI":"10.3390\/vaccines7030096"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Bloom, K., van den Berg, F., and Arbuthnot, P. (2020). Self-amplifying RNA vaccines for infectious diseases. Gene Ther., 10.","DOI":"10.1038\/s41434-020-00204-y"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1089\/hum.2017.121","article-title":"Improvement of In Vivo Expression of Genes Delivered by Self-Amplifying RNA Using Vaccinia Virus Immune Evasion Proteins","volume":"28","author":"Beissert","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.stem.2013.06.001","article-title":"Efficient generation of human iPSCs by a synthetic self-replicative RNA","volume":"13","author":"Yoshioka","year":"2013","journal-title":"Cell Stem Cell"},{"key":"ref_51","first-page":"747","article-title":"Flaviviruses","volume":"Volume One","author":"Knipe","year":"2013","journal-title":"Fields Virology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12985-018-0970-2","article-title":"Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope","volume":"15","author":"Metz","year":"2018","journal-title":"Virol. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"206","DOI":"10.15252\/embr.201745302","article-title":"The bright and the dark side of human antibody responses to flaviviruses: Lessons for vaccine design","volume":"19","author":"Rey","year":"2018","journal-title":"EMBO Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/femsre\/fuu004","article-title":"Receptors and routes of dengue virus entry into the host cells","volume":"39","author":"Freire","year":"2015","journal-title":"FEMS Microbiol Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1126\/science.1153263","article-title":"The flavivirus precursor membrane-envelope protein complex: Structure and maturation","volume":"319","author":"Li","year":"2008","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1038\/emboj.2009.245","article-title":"Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody","volume":"28","author":"Cherrier","year":"2009","journal-title":"EMBO J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/embor.2011.75","article-title":"Maturation of flaviviruses starts from one or more icosahedrally independent nucleation centres","volume":"12","author":"Plevka","year":"2011","journal-title":"EMBO Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/jvi.69.2.695-700.1995","article-title":"Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH","volume":"69","author":"Allison","year":"1995","journal-title":"J. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Zaitseva, E., Yang, S.T., Melikov, K., Pourmal, S., and Chernomordik, L.V. (2010). Dengue virus ensures its fusion in late endosomes using compartment-specific lipids. PLoS Pathogens, 6.","DOI":"10.1371\/journal.ppat.1001131"},{"key":"ref_60","first-page":"311","article-title":"Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered","volume":"42","author":"Halstead","year":"1970","journal-title":"Yale J. Biol. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Balsitis, S.J., Williams, K.L., Lachica, R., Flores, D., Kyle, J.L., Mehlhop, E., Johnson, S., Diamond, M.S., Beatty, P.R., and Harris, E. (2010). Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathogens, 6.","DOI":"10.1371\/journal.ppat.1000790"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.4049\/jimmunol.176.5.2825","article-title":"The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection","volume":"176","author":"Huang","year":"2006","journal-title":"J. Immun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1099\/vir.0.82537-0","article-title":"Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells","volume":"88","author":"Chareonsirisuthigul","year":"2007","journal-title":"J. Gen. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1126\/science.1185181","article-title":"Cross-reacting antibodies enhance dengue virus infection in humans","volume":"328","author":"Dejnirattisai","year":"2010","journal-title":"Science"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1126\/science.abb6143","article-title":"Zika virus infection enhances future risk of severe dengue disease","volume":"369","author":"Katzelnick","year":"2020","journal-title":"Science"},{"key":"ref_67","first-page":"351","article-title":"Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals","volume":"215","author":"Henein","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1016\/j.vaccine.2017.09.089","article-title":"Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age","volume":"35","author":"Halstead","year":"2017","journal-title":"Vaccine"},{"key":"ref_69","unstructured":"(2018). Dengue Vaccine: WHO position paper\u2014September 2018. Wkly. Epidemiol. Record, 93, 457\u2013476."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/4031","article-title":"In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model","volume":"4","author":"Mandl","year":"1998","journal-title":"Nat. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1073\/pnas.0307145101","article-title":"Mimicking live flavivirus immunization with a noninfectious RNA vaccine","volume":"101","author":"Kofler","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"15107","DOI":"10.1128\/JVI.79.24.15107-15113.2005","article-title":"Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus","volume":"79","author":"Aberle","year":"2005","journal-title":"J. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/319857","article-title":"Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus","volume":"183","author":"Fleeton","year":"2001","journal-title":"J. Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJMra1808246","article-title":"Zika Virus Infection\u2014After the Pandemic","volume":"381","author":"Musso","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.4269\/ajtmh.16-0306","article-title":"Guillain-Barre Syndrome After Zika Virus Infection in Brazil","volume":"95","author":"Vasilakis","year":"2016","journal-title":"Am. J. Trop Med. Hyg."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bjid.2018.02.005","article-title":"Prevalence of Guillain-Barre syndrome among Zika virus infected cases: A systematic review and meta-analysis","volume":"22","author":"Barbi","year":"2018","journal-title":"Braz J. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1101\/gad.298216.117","article-title":"How does Zika virus cause microcephaly?","volume":"31","author":"Wen","year":"2017","journal-title":"Genes Dev."},{"key":"ref_78","unstructured":"(2021, January 07). Congenital Zika Syndrome & Other Birth Defects, Available online: https:\/\/www.cdc.gov\/pregnancy\/zika\/testing-follow-up\/zika-syndrome-birth-defects.html."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.coi.2018.04.024","article-title":"Zika virus vaccines: Immune response, current status, and future challenges","volume":"53","author":"Richner","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA Vaccines Protect against Zika Virus Infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.06.040","article-title":"Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease","volume":"170","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"ref_82","unstructured":"(2020, April 14). Interim Phase 1 Data for Zika Virus Vaccine (mRNA-1893). Available online: https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/moderna-highlights-opportunity-mrna-vaccines-its-first-vaccines."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41598-017-00193-w","article-title":"An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model","volume":"7","author":"Chahal","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"eaba5068","DOI":"10.1126\/sciadv.aba5068","article-title":"Development of a potent Zika virus vaccine using self-amplifying messenger RNA","volume":"6","author":"Luisi","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.ymthe.2018.07.010","article-title":"A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika","volume":"26","author":"Erasmus","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.aaf8505","article-title":"Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection","volume":"353","author":"Stettler","year":"2016","journal-title":"Science"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1126\/science.aal4365","article-title":"Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity","volume":"356","author":"Bardina","year":"2017","journal-title":"Science"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature12060","article-title":"The global distribution and burden of dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.3389\/fimmu.2019.01424","article-title":"A Modified mRNA Vaccine Targeting Immunodominant NS Epitopes Protects Against Dengue Virus Infection in HLA Class I Transgenic Mice","volume":"10","author":"Roth","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.omtm.2020.07.013","article-title":"Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice","volume":"18","author":"Zhang","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Wollner, C.J., Richner, M., Hassert, M.A., Pinto, A.K., Brien, J.D., and Richner, J.M. A mRNA-LNP vaccine against Dengue Virus elicits robust, serotype-specific immunity. bioRxiv, 2021.","DOI":"10.1101\/2021.01.05.425517"},{"key":"ref_94","unstructured":"(2021, January 07). Powassan Statistics & Maps, Available online: https:\/\/www.cdc.gov\/powassan\/statistics.html."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1146\/annurev-ento-112408-085446","article-title":"Update on Powassan virus: Emergence of a North American tick-borne flavivirus","volume":"55","author":"Ebel","year":"2010","journal-title":"Annu. Rev. Entomol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1089\/vbz.2017.2110","article-title":"Powassan Virus: An Emerging Arbovirus of Public Health Concern in North America","volume":"17","author":"Hermance","year":"2017","journal-title":"Vector Borne Zoonotic Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1016\/j.celrep.2018.11.082","article-title":"An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections","volume":"25","author":"VanBlargan","year":"2018","journal-title":"Cell Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41564-020-0714-0","article-title":"The continued threat of emerging flaviviruses","volume":"5","author":"Pierson","year":"2020","journal-title":"Nat. Microbiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ni.3058","article-title":"A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus","volume":"16","author":"Dejnirattisai","year":"2015","journal-title":"Nat. Immunol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/2\/148\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:23:18Z","timestamp":1760160198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/2\/148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":100,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["vaccines9020148"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9020148","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,12]]}}}